Moderna vs Novavax
MRNA and NVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRNA and NVAX compare
Moderna is the larger company, worth 53 times as much as Novavax ($88.5B against $1.7B).
Moderna grew revenue faster over the last twelve months (−27.6% versus −61.6% for Novavax).
Novavax keeps more of each dollar of sales as profit, with a net margin of −59.9% compared with −141% at Moderna.
Moderna scores higher on the StockData Score (5 against 3 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRNA | NVAX |
|---|---|---|
| Size and price | ||
| Market cap | $88.5B | $1.7B |
| Share price | $221.72 | $10.08 |
| Change, 1 year | 798% | 20.3% |
| Change, 5 years | −6.4% | −93.7% |
| Beta (5Y) | 1.11 | 1.99 |
| Employees | 4,700 | 749 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 39.7× | 4.0× (better) |
| P/B | 13.1× | – |
| FCF yield | −1.4% | – |
| Fair value | $33.24 | – |
| Margin of safety | −567% | – |
| Growth | ||
| Revenue growth (TTM) | −27.6% (better) | −61.6% |
| Revenue growth, 5Y average | 19.3% (better) | 18.8% |
| Net income growth (TTM) | – | −159% |
| EPS growth (TTM) | – | −168% |
| Profitability | ||
| Gross margin | 23.4% | 78.6% (better) |
| Operating margin | −149% | −56.6% (better) |
| Net margin | −141% | −59.9% (better) |
| FCF margin | −55.8% | – |
| Return on equity | −39.0% | – |
| Return on invested capital | −80.9% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Interest coverage | – | −10.7× |
| Current ratio | 2.29 | 2.33 (better) |
| Altman Z-score | 12.86 (better) | −5.74 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.9% | 71.2% |
| Held by insiders | 5.6% | 9.2% |
| Insider net buying, 12 months | −$64.6M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.2% | 30.7% |
Go deeper
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
- NVAX stock overview
- NVAX income statement
- NVAX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.